812 related articles for article (PubMed ID: 28821685)
1. Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan.
Suzuki S; Ishikawa N; Konoeda F; Seki N; Fukushima S; Takahashi K; Uhara H; Hasegawa Y; Inomata S; Otani Y; Yokota K; Hirose T; Tanaka R; Suzuki N; Matsui M
Neurology; 2017 Sep; 89(11):1127-1134. PubMed ID: 28821685
[TBL] [Abstract][Full Text] [Related]
2. Clinical characteristics, treatment and outcome of nivolumab-induced myasthenia gravis.
Wang C; Zeng H; Fang W; Song L
Invest New Drugs; 2023 Apr; 41(2):333-339. PubMed ID: 36988830
[TBL] [Abstract][Full Text] [Related]
3. Nivolumab and Ipilimumab-induced myositis and myocarditis mimicking a myasthenia gravis presentation.
Valenti-Azcarate R; Esparragosa Vazquez I; Toledano Illan C; Idoate Gastearena MA; Gállego Pérez-Larraya J
Neuromuscul Disord; 2020 Jan; 30(1):67-69. PubMed ID: 31839404
[TBL] [Abstract][Full Text] [Related]
4. Myasthenic crisis and polymyositis induced by one dose of nivolumab.
Kimura T; Fukushima S; Miyashita A; Aoi J; Jinnin M; Kosaka T; Ando Y; Matsukawa M; Inoue H; Kiyotani K; Park JH; Nakamura Y; Ihn H
Cancer Sci; 2016 Jul; 107(7):1055-8. PubMed ID: 27420474
[TBL] [Abstract][Full Text] [Related]
5. [An autopsy case of nivolumab-induced myasthenia gravis and myositis].
Sawai T; Hosokawa T; Shigekiyo T; Ogawa S; Sano E; Arawaka S
Rinsho Shinkeigaku; 2019 Jun; 59(6):360-364. PubMed ID: 31142711
[TBL] [Abstract][Full Text] [Related]
6. Nivolumab-associated myositis myocarditis and myasthenia and anti-striated muscle antibodies.
Fazal M; Prentice DA; Kho LK; Fysh E
Intern Med J; 2020 Aug; 50(8):1003-1006. PubMed ID: 33306231
[TBL] [Abstract][Full Text] [Related]
7. Coexisting myasthenia gravis, myositis, and polyneuropathy induced by ipilimumab and nivolumab in a patient with non-small-cell lung cancer: A case report and literature review.
Chen JH; Lee KY; Hu CJ; Chung CC
Medicine (Baltimore); 2017 Dec; 96(50):e9262. PubMed ID: 29390370
[TBL] [Abstract][Full Text] [Related]
8. Improved outcomes with early immunosuppression in patients with immune-checkpoint inhibitor induced myasthenia gravis, myocarditis and myositis: a case series.
Weaver JM; Dodd K; Knight T; Chaudhri M; Khera R; Lilleker JB; Roberts M; Lorigan P; Cooksley T
Support Care Cancer; 2023 Aug; 31(9):518. PubMed ID: 37572133
[TBL] [Abstract][Full Text] [Related]
9. Acetylcholine receptor binding antibody-associated myasthenia gravis and rhabdomyolysis induced by nivolumab in a patient with melanoma.
Shirai T; Sano T; Kamijo F; Saito N; Miyake T; Kodaira M; Katoh N; Nishie K; Okuyama R; Uhara H
Jpn J Clin Oncol; 2016 Jan; 46(1):86-8. PubMed ID: 26491202
[TBL] [Abstract][Full Text] [Related]
10. Nivolumab-induced Myositis and Myocarditis with Positive Anti-titin Antibody and Anti-voltage-gated Potassium Channel Kv1.4 Antibody.
Ono R; Iwai Y; Yamazaki T; Takahashi H; Hori Y; Fukushima K; Saotome T
Intern Med; 2022 Oct; 61(19):2973-2979. PubMed ID: 35314545
[TBL] [Abstract][Full Text] [Related]
11. Durvalumab-induced myocarditis, myositis, and myasthenia gravis: a case report.
Cham J; Ng D; Nicholson L
J Med Case Rep; 2021 May; 15(1):278. PubMed ID: 34053457
[TBL] [Abstract][Full Text] [Related]
12. [A case of myasthenia gravis and myositis induced by nivolumab].
Konoeda F; Suzuki S; Nishimoto Y; Hoshino H; Takagi M
Rinsho Shinkeigaku; 2017 Jul; 57(7):373-377. PubMed ID: 28674287
[TBL] [Abstract][Full Text] [Related]
13. Myositis as a neuromuscular complication of immune checkpoint inhibitors.
Vermeulen L; Depuydt CE; Weckx P; Bechter O; Van Damme P; Thal DR; Claeys KG
Acta Neurol Belg; 2020 Apr; 120(2):355-364. PubMed ID: 31993961
[TBL] [Abstract][Full Text] [Related]
14. Characterization of Immune Checkpoint Inhibitor-Induced Myasthenia Gravis Using the US Food and Drug Administration Adverse Event Reporting System.
Niimura T; Zamami Y; Miyata K; Mikami T; Asada M; Fukushima K; Yoshino M; Mitsuboshi S; Okada N; Hamano H; Sakurada T; Matsuoka-Ando R; Aizawa F; Yagi K; Goda M; Chuma M; Koyama T; Izawa-Ishizawa Y; Yanagawa H; Fujino H; Yamanishi Y; Ishizawa K
J Clin Pharmacol; 2023 Apr; 63(4):473-479. PubMed ID: 36453166
[TBL] [Abstract][Full Text] [Related]
15. Immune Checkpoint Inhibitor-Induced Myocarditis with Myositis/Myasthenia Gravis Overlap Syndrome: A Systematic Review of Cases.
Pathak R; Katel A; Massarelli E; Villaflor VM; Sun V; Salgia R
Oncologist; 2021 Dec; 26(12):1052-1061. PubMed ID: 34378270
[TBL] [Abstract][Full Text] [Related]
16. [A case of anti-titin antibody positive nivolumab-related necrotizing myopathy with myasthenia gravis].
Isami A; Uchiyama A; Shimaoka Y; Suzuki S; Kawachi I; Fujita N
Rinsho Shinkeigaku; 2019 Jul; 59(7):431-435. PubMed ID: 31243249
[TBL] [Abstract][Full Text] [Related]
17. Myositis as an adverse event of immune checkpoint blockade for cancer therapy.
Shah M; Tayar JH; Abdel-Wahab N; Suarez-Almazor ME
Semin Arthritis Rheum; 2019 Feb; 48(4):736-740. PubMed ID: 29909921
[TBL] [Abstract][Full Text] [Related]
18. Severe Myositis, Myocarditis, and Myasthenia Gravis with Elevated Anti-Striated Muscle Antibody following Single Dose of Ipilimumab-Nivolumab Therapy in a Patient with Metastatic Melanoma.
Fazel M; Jedlowski PM
Case Reports Immunol; 2019; 2019():2539493. PubMed ID: 31183226
[TBL] [Abstract][Full Text] [Related]
19. Autoimmune targets of heart and skeletal muscles in myasthenia gravis.
Suzuki S; Utsugisawa K; Yoshikawa H; Motomura M; Matsubara S; Yokoyama K; Nagane Y; Maruta T; Satoh T; Sato H; Kuwana M; Suzuki N
Arch Neurol; 2009 Nov; 66(11):1334-8. PubMed ID: 19752287
[TBL] [Abstract][Full Text] [Related]
20. Immune checkpoint-mediated myositis and myasthenia gravis: A case report and review of evaluation and management.
Kang KH; Grubb W; Sawlani K; Gibson MK; Hoimes CJ; Rogers LR; Lavertu P; Yao M
Am J Otolaryngol; 2018; 39(5):642-645. PubMed ID: 29903623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
